It is currently Fri Nov 21, 2014 4:33 pm

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.


NEW VACCINE TESTED AGAINST AUTOIMMUNE DISEASES

http://nocamels.com/2012/01/new-vaccine ... -diseases/
ISRAELI scientists from Weizmann Institute of silence think they have made progress what could be significant progress in the treatment of autoimmune diseases
read more from the attached
regards
seeva
Read more : NEW VACCINE TESTED AGAINST AUTOIMMUNE DISEASES | Views : 273 | Replies : 1


VACCINE AGAINST MS BEING DEVELOPED AT BAYLOR INSTITUTE FOR I

Vaccine Against MS Being Developed at Baylor Institute for Immunology Research
FRIENDS PL READ
SEEVA
Read more : VACCINE AGAINST MS BEING DEVELOPED AT BAYLOR INSTITUTE FOR I | Views : 223 | Replies : 1


IVIG

Lyme disease triggered my MS about 25 yrs ago. There was a time when I took ivig50 g per month and it was helping. Thus January cigna denied coverage. Had to go to HR, got it covered again. Getting port on Tuesday.
I have tried Copaxone, calcium EAP, Prokarin, B1/liver extract shots but I am hoping the ivig will help me get to a better place.

Just sharing my experience w IVIG
Read more : IVIG | Views : 121 | Replies : 0


Secondary progressive MS therapy MIS416 dosing trial....

Secondary progressive MS therapy MIS416 dosing trial underway

New Zealand and Australia-based Innate Immunotherapeutics Limited, a medical biotechnology company with offices in Sydney and Auckland, has issued an update regarding its Phase 2B trial for secondary progressive multiple sclerosis (SPMS) and other recent activities.

The Phase 2B MIS416 trial Patient dosing with MIS416 is now underway at the West Australian Neuroscience Institute (WANRI) in Perth and at Nucleus Network’s AMREP Centre for Clinical Studies in ...
Read more : Secondary progressive MS therapy MIS416 dosing trial.... | Views : 156 | Replies : 0


Anemone toxin inhibits KV1.3

The Alliance for Children's Therapeutics in collaboration with Dr. Anne Stevens of Seattle Children's Hospital and Kineta Biotech are developing a synthetic protein known as Shk-186. Based on a toxin from the Sun Anemone, Shk-186 inhibits the potassium channel KV1.3 in effector memory T cells and blocks the proinflammatory cytokine cascade leading to autoimmunity.

http://www.childrenstherapeutics.org/treatments.html

http://www.kinetabio.com/autoimmune.html

http://www.seattlechildrens.org/researc ... evens-lab/ ...
Read more : Anemone toxin inhibits KV1.3 | Views : 152 | Replies : 0


Synthetic protein targets EBV

UW researchers at the Institute of Protein Design have developed a synthetic protein called BINDI which binds to the Epstein-Barr Virus (EBV) protein BHRF1 responsible for immortalizing cells. Inhibition of BHRF1, a BCL2 homologue, may prove to be a useful treatment for EBV related cancers and other conditions stemming from EBV.

http://www.ipd.uw.edu/designer-proteins ... cer-cells/

http://www.cell.com/cell/abstract/S0092 ... %2900613-8
Read more : Synthetic protein targets EBV | Views : 124 | Replies : 0


Drug effectiveness in doubt.

On March 21, 2013 it was announced that Professor George C. Ebers, MD, of University of Oxford in London, had been chosen to receive the National MS Society/American Academy of Neurology’s 2013 John Dystel Prize for Multiple Sclerosis. The following quotes come from http://www.nationalmssociety.org site.

QUOTE
"His studies of twins have shown that susceptibility is partly genetic and partly environmental, indicating that MS is a complex genetic disease. These ...
Read more : Drug effectiveness in doubt. | Views : 295 | Replies : 0


Positive data from multiple dose phase1 trial of CTP-354

Concert Pharmaceuticals Inc. announced Phase 1 data of CTP-354, a novel, potentially first-in-class, non-sedating, once-daily oral treatment for spasticity. In this multiple ascending dose trial, no sedation or ataxia was observed with CTP-354 and the drug was generally well tolerated across all dose cohorts.

Concert expects to initiate a Phase 2 clinical trial evaluating CTP-354 in patients with spasticity associated with spinal cord injury by the end of 2014..... Read More - http://www.ms-uk.org/emergingtherapies
Read more : Positive data from multiple dose phase1 trial of CTP-354 | Views : 306 | Replies : 0


Tecfidera versus aubagio

In brief, I was diagnosed with ms more than 20 years ago. Based on the treatments available then, I chose to wait as the disease was mostly a symptomatic. Now in my late 40's it has come back with a vengeance. MRI shows multiple lesions and I'm having multiple episodes especially with weakness in my left leg. My neurologist wants me to start medication now and my options are tecfidera or aubagio. I'm leaning towards ...
Read more : Tecfidera versus aubagio | Views : 514 | Replies : 1


 

Login  •  Register


Statistics

Total posts 221669 • Total topics 23013 • Total members 14538


Contact us | Terms of Service